Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Steady growth… - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 28, 2002

    Sun Pharma: Steady growth…

    Sun Pharma has reported over 10% growth in sales during September quarter 2002. Operating costs grew at a slower rate, consequently expanding the operating margins to 28.5%. Operating profit was up over 16% YoY during the quarter. A 43% growth in tax provisioning saw net profit growth slow down to 11% YoY.

    (Rs m) 2QFY02 2QFY03 Change
    Net Sales 1,962 2,166 10.4%
    Other Income 23 12 -47.8%
    Expenditure 1,431 1,549 8.3%
    Operating Profit (EBDIT) 531 617 16.2%
    Operating Profit Margin (%) 27.1% 28.5%  
    Interest (net) -12 -12 2.6%
    Depreciation 43 50 16.7%
    Profit before Tax 522 591 13.1%
    Tax 40 58 43.1%
    Profit after Tax 482 533 10.6%
    Net profit margin (%) 24.6% 24.6%  
    Effective tax rate (%) 7.7% 9.8%  
    No. of Shares (eoy) (m) 46.8 46.8  
    Diluted earnings per share* 41.2 45.6  
    P/E ratio   12.3  
    (* annualised)      

    The board has approved the split of the company's equity shares of Rs 10 each into 2 equity shares of Rs 5 each. The company has also decided to buyback its equity shares with a maximum outlay of Rs 1,200 m for a maximum price of Rs 750 per equity share of Rs 10 each. Both the aforesaid moves are subject to shareholder approval. The shareholders meeting in both the purposes will be held on December 20, 2002.

    Cost break-up
    (Rs m) 2QFY02 2QFY03 % change
    - (Increase) / decrease in stock in trade -5.1 -32.3  
    - Material Cost 806 855  
    Total Cost of goods 801 822 2.6%
    - Staff Cost 101 122 21.1%
    - Indirect taxes 216 269 24.8%
    - Other Expenditure 313 336 7.3%
    Total expenditure 1431 1549 8.3%

    The maximum buyback price is at a 34% premium to the current share price of Rs 560. At the current price, the stock is trading at 12.3x annualised 2QFY03 earnings. The stock may see some strength owing to the buyback offer in the short term.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Steady growth…". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 (Close)


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Quarterly Results With Charts